Navigation Links
Jeremy Levin Joins Bristol-Myers Squibb as Senior Vice President of External Science, Technology and Licensing
Date:9/27/2007

NEW YORK, Sept. 27 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb (NYSE: BMY) announced today that Dr. Jeremy Levin has joined the company's Research and Development organization as senior vice president, External Science, Technology and Licensing. He will report to Dr. Elliott Sigal, chief scientific officer and president, Research and Development.

"I am delighted Jeremy has joined our R&D organization at this critical juncture for Bristol-Myers Squibb, as we look to further build our robust pipeline in areas of significant unmet medical need and to transform our pharmaceutical business for the future," said Dr. Sigal. "Jeremy's extensive global network in the pharmaceutical, biotechnology and venture industries will help ensure that we remain a leader in forging creative partnerships to advance the development of novel medicines."

Prior to joining Bristol-Myers Squibb, Dr. Levin served as Global Head of Business Development and Strategic Alliances at the Novartis Institutes of Biomedical Research. In that capacity, he and his team secured hundreds of collaborations in more than 20 countries since 2003. Prior to his tenure at Novartis, Dr. Levin held leadership positions in several biotechnology companies, including Physiome Sciences, Inc. and Cadus Pharmaceutical Corporation. He also was managing director of Perseus Capital LLC, a life sciences venture fund. He has served on the executive committees and boards of several public biosciences companies, as well as the Executive Committee of BIO and the boards of the Biotechnology Institute and the New York Biotechnology Association.

"I am excited about the tremendous opportunity at Bristol-Myers Squibb," said Dr. Levin. "I am especially looking forward to working with Elliott, his team and all the outstanding people at this company. I will look to aggressively complement Bristol-Myers Squibb's world class internal team, capabilities and pipeline with the best science and medicines around the globe."

Dr. Levin received a B.A. (First Class Honors) in Zoology, and M.A. and Doctorate (D.Phil.) in Cell Biology and Chromatin Structure from the University of Oxford, as well as a Medical Degree (MB BChir) from the University of Cambridge. He practiced as a physician in internal medicine in several university hospitals, including Hammersmith Hospital in London. In 2005, Dr. Levin was awarded the Albert Einstein Award for Outstanding Achievement in the Life Sciences.

Bristol-Myers Squibb is a global pharmaceutical and related healthcare products company whose mission is to extend and enhance human life.


'/>"/>
SOURCE Bristol-Myers Squibb
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Ranbaxy joins hand with Cipla to co-market ciprofloxacin
2. Rat joins list of cloned animals
3. Richard Gere Joins Indian Stars For Fight Against AIDS
4. Enbrel Joins with Methotrexate to Cure Rheumatoid Arthritis
5. Anoushka Joins Hands With WFP to Feed the Poor
6. India Joins Hands With Global Body for Vaccine Research
7. Another Statewide Organization Joins the Fight Against Assisted Suicide
8. Two-year-old Joins Mensa, Becomes Its Youngest Ever Genius
9. Senior drug card saves little
10. Reducing Depression In Seniors
11. A sharp increased in senior citizens: set to outpace children.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Angeles, CA (PRWEB) , ... February 11, 2016 , ... ... Loss System, a product marketed as a weight loss dietary supplement, is being recalled ... medical group Beverly Hills Physicians, because there is not a single supplement on the ...
(Date:2/11/2016)... ... ... Registered nurses, licensed practical nurses and nursing aides who treat stroke patients ... to Heal” on Thursday, February 25 from 9:00 to 11:00 a.m. at the ... of ANSA Consultants, who will discuss clinical best practices throughout the continuum of stroke ...
(Date:2/11/2016)... ... ... The Journal of Pain Research has seen a significant increase in ... from the Scopus database (Elsevier B.V.) and is a measure of a journal's impact. ... a three year period and also the importance of the journals where the citations ...
(Date:2/11/2016)... IL (PRWEB) , ... February 11, 2016 , ... ... to the healthcare industry, ranked among the top five firms in the “2015/2016 ... and HIT Implementation Support and Staffing. KLAS is a research and insights firm ...
(Date:2/11/2016)... ... February 11, 2016 , ... Thermi™, a world leader in ... announce the promotions of Allison Kelly to executive vice president of the company’s ... president of North American capital sales, and Wendy Oseas to vice president of ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... BUDAPEST , Ungarn, February 12, 2016 ... ein Medizintechnikunternehmen, das sich auf den ungedeckten ... gab heute positive Ergebnisse seines klinischen Forschungsprogramms ... und Asthma-Patienten beschäftigt, ergab Verbesserungen ihrer respiratorischen ... Indiso ltd , ein Medizintechnikunternehmen, das ...
(Date:2/11/2016)... , Feb. 11, 2016 Stem cells are ... characterized by self-renewal and the capacity to differentiate into ... new discovery, as the first mouse embryonic stem cells ... not until 1995 that the first culturing of embryonic ... cells were not produced until 2006 As a result ...
(Date:2/11/2016)... , Feb. 11, 2016  Walgreens has committed to ... states and Washington, D.C. as part ... that was commended by shareholder advocacy organization As You Sow. ... You Sow. "Many people hold on to unneeded drugs because ... have tragic consequences." --> Conrad MacKerron , ...
Breaking Medicine Technology: